How HCA Healthcare, Inc. Makes Money

The stakes are high: HCA must prove it can grow volumes and pricing power in an environment where Medicare payment rates are constrained, commercial insurers are aggressively managing costs, and the site-neutral payment movement threatens to compress hospital-based reimbursement. Medicare and Medicaid reimbursement rates are set by federal and state governments, creating pricing pressure that HCA offsets through volume growth, acuity mix management, and operational efficiency. Supply costs represent the second-largest expense category, followed by professional fees, depreciation, and interest expense. HCA operates its own group purchasing organization, HealthTrust, which leverages the purchasing volume of approximately 1,600 hospitals and 37,000 non-acute care sites to negotiate favorable pricing on pharmaceuticals, medical devices, and supplies. HCA's scale and quality metrics provide leverage in these negotiations, but the trend toward value-based payment and risk-sharing contracts requires operational capabilities that differ from traditional fee-for-service hospital management. The company's cost structure reflects the labor-intensive nature of hospital operations: salaries and benefits represent approximately 45.4% of revenue, supply costs are the second-largest expense, and professional fees continue to grow as physician employment subsidies remain a structural challenge. Medicare payment updates have historically lagged medical inflation, and the site-neutral payment movement — championed by the Medicare Payment Advisory Commission (MedPAC) and some congressional proposals — threatens to reduce reimbursement for hospital-based outpatient services by aligning them with lower freestanding facility rates. In many of its markets, HCA holds dominant or duopolistic positions that provide pricing power in commercial insurance negotiations and operational efficiencies from shared services, centralized supply chain management, and integrated electronic health records. HealthTrust leverages aggregate purchasing volume to negotiate pricing on pharmaceuticals, medical devices, and supplies that smaller competitors cannot match. The company is 80% contracted for 2025 and 60% contracted for 2026, with mid-single-digit commercial rate escalators providing some pricing protection. Long-term, HCA must navigate the transition from fee-for-service to value-based care.

That is HCA Healthcare in 2024, a company that has spent 57 years building the largest for-profit hospital network in America while navigating the existential risks of Medicare fraud investigations, leveraged buyouts, and the structural shift from inpatient to outpatient care. HCA's capital allocation strategy prioritizes organic growth through bed additions, de novo hospital construction, and ambulatory expansion; maintenance capital expenditures to preserve existing facilities; strategic tuck-in acquisitions to fill geographic gaps; and shareholder returns through dividends and share repurchases. Tenet operates approximately 60 hospitals and 600+ ambulatory surgery centers, with a stronger concentration in urban markets and a significant ambulatory platform through its United Surgical Partners International subsidiary. HCA's competitive response includes expanding its own urgent care network, improving ER throughput times, and using its scale to negotiate favorable in-network status with commercial insurers. Revenue growth was driven by same-facility admissions growth of 4.9%, same-facility equivalent admissions growth of 4.5%, same-facility emergency room visit growth of 4.9%, and a 3.2% increase in revenue per equivalent admission to $17,695. The stock trades at approximately $372.13 per share with a P/E ratio of 12.82x and a forward P/E of 12.27x, reflecting the market's view of HCA as a mature, cash-generative business with limited growth optionality. While HCA has reduced contract labor from peak levels — contract labor represented 4.4% of total labor costs in Q1 2025, down from 5.1% in Q1 2024 — the company must continue investing in workforce development, including its Galen College of Nursing pipeline, to avoid reliance on expensive temporary staffing. In Q1 2025, HCA reported a 15% year-over-year decline in exchange equivalent admissions and a 16% increase in uninsured admissions, with management noting that over half of the uninsured growth was due to patients moving from exchanges. Finally, regulatory and political uncertainty — including potential changes to the Affordable Care Act, Medicaid expansion policies, and Medicare Advantage program integrity initiatives — creates strategic planning challenges that HCA must navigate while maintaining its growth trajectory. Fourth, HCA's workforce development pipeline — anchored by Galen College of Nursing, in which HCA acquired a majority stake in 2020 — provides a sustainable source of registered nurses trained specifically for HCA's operational model. HCA Healthcare's growth strategy under CEO Sam Hazen emphasizes organic network development, operational efficiency, and disciplined capital allocation rather than large-scale acquisitions. The first pillar, organic network development, involves adding hospital beds, building de novo hospitals in high-growth Sun Belt markets, and expanding the ambulatory care network. Specific initiatives include AI-driven clinical documentation to reduce physician administrative burden, nursing handoff protocols to improve care transitions, case management optimization to reduce length of stay, and revenue cycle automation to improve collections. The third pillar, workforce development, addresses the nursing shortage through Galen College of Nursing expansion, partnerships with external nursing schools, nurse residency programs, and competitive compensation packages. The fourth pillar, capital allocation discipline, balances growth investments with shareholder returns. The company lowered its targeted leverage range to 2.75x – 3.75x from 3x – 4x, reflecting confidence in cash flow stability and a desire to maintain investment-grade credit access. Management has indicated that 2025 will focus on organic growth rather than significant M&A, though tuck-in acquisitions of ambulatory facilities, urgent care centers, and physician practices will continue to fill geographic gaps and strengthen market density. HCA's strategic horizon is defined by three concurrent imperatives: sustaining volume growth in a maturing hospital market, expanding ambulatory and lower-cost care settings to capture site-of-care migration, and defending reimbursement rates against Medicare payment constraints and site-neutral payment proposals. Volume growth remains the dominant near-term variable. Management has guided to 3 – 4% equivalent admissions growth in 2025, supported by continued population inflows in Sun Belt markets, network expansion including 4% more sites of care and 1% more hospital beds, and operational initiatives to improve emergency department throughput and operating room efficiency. The company is also investing in de novo hospital construction in high-growth metropolitan areas, with a multi-year capital pipeline of $5.5 – $6 billion in approved projects. The ambulatory expansion strategy centers on growing ASCs, freestanding emergency rooms, and urgent care centers to match payer preferences for lower-cost settings. The workforce development strategy focuses on reducing contract labor dependence and improving nurse retention. HCA has expanded Galen College of Nursing programs and partnered with other nursing schools to hire graduate nurses. Success in value-based contracts requires investments in care coordination, population health management, and risk-bearing capabilities that differ from traditional hospital operations. In July 1997, federal agents raided Columbia/HCA hospitals and offices in seven states, launching an investigation into Medicare fraud, false billing, and illegal kickbacks to physicians. The company's new leadership, under Thomas Frist Jr. immediately changed course — ending physician partnerships, creating a compliance program, and cooperating with federal investigators. The Department of Justice characterized the settlement as 'by far the largest recovery ever reached by the government in a health care fraud investigation.' The company rebranded back to HCA, divested non-core assets, and focused on operational recovery. In the public markets, HCA has pursued a strategy of organic growth, operational efficiency, and disciplined capital allocation. The COVID-19 pandemic tested HCA's operational resilience, with surge capacity demands followed by a deferred-care recovery that drove volume growth in 2021 – 2024.